Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biafine for Radiation-Induced Skin Toxicity in Head and Neck Cancer
NCT00006481Phase 3Completed
- Sponsor
- NRG Oncology
- Start
- Oct 2000
- Primary completion
- Aug 2002
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of atopiclair in radiation dermatitis (3 arms), sponsored by NRG Oncology. Primary endpoint: Incidence of Grade 2 or higher radiation-induced skin toxicity up to 8 weeks. Started Oct 2000; status: completed.
02
Drugs
atopiclair
03
Conditions
radiation dermatitis
Beyond the preview
Go deeper on NCT00006481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006481.